Skip to search formSkip to main contentSkip to account menu

Antihemophilic Factor, Human Recombinant 1 UNT Injection [Kovaltry]

Known as: Kovaltry 1 UNT Injection, ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT 3000 [iU] in 5 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Kovaltry], ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT 2000 [iU] in 5 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Kovaltry] 
National Institutes of Health

Related topics

Related topics

9 relations
Antihemophilic Factor, Human RecombinantCalcium ChlorideGlycineHistidine

Broader (1)

Antihemophilic Factor, Human Recombinant 1 UNT Injection

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
To report interim data from TAURUS, a study assessing real‐world prophylactic treatment with unmodified, full‐length recombinant… 
2020
2020
BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
BAY 81‐8973 (Kovaltry®), a full‐length, unmodified, recombinant human factor VIII, provided excellent bleeding control for… 
2019
2019
Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
BAY 81‐8973 (Kovaltry®) is a full‐length, unmodified recombinant human factor VIII approved in China for prophylaxis and on… 
Review
2019
Review
2019
Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits
The current interest in recombinant factor VIII (rFVIII) products stems from the fact that they offer a technological solution to… 
Review
2018
Review
2018
BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review
BAY 81-8973 (Kovaltry®) is an unmodified, full-length recombinant factor VIII (rFVIII) approved for the prevention and treatment… 
Review
2018
Review
2018
Bay 81-8973 in the Real World: Clinical Effectiveness and Safety in Patients with Hemophilia Α across the US and Europe
Background: BAY 81-8973 (Kovaltry®, Bayer) is an unmodified full-length recombinant FVIII launched in 2016 in Europe and the US… 
2017
2017
[Use of Kovaltry® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials]
Farmeconomia. Health economics and therapeutic pathways 2017; 18(1) © SEEd All rights reserved Dal punto di vista economico, il… 
Review
2016
Review
2016
BAY 81-8973 (Octocog Alfa; Kovaltry®): A Review in Haemophilia A
BAY 81-8973 (octocog alfa; Kovaltry®) is an unmodified, full-length, recombinant factor VIII (FVIII) concentrate with the same… 
2016
2016
[Kovaltry® for the replacement therapy in patients with Hemophilia A]
vazioni della World Federation of Hemophilia riportando una prevalenza della malattia di 6,2/100.000 abitanti; nel 2013, dei 3… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)